Susan Stayn is a Stanford lawyer who has published comparative analyses of state regulatory schemes supporting stem cell research.
¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤
By Susan Stayn
Since August 9, 2001—the date George W. Bush restricted the use of federal funds for human embryonic stem cell (hESC) research—at least 11 states have committed to advance the research through formal legal measures [...]
Entries from October 2007
October 30, 2007
Cell Lines, State Lines
October 29, 2007
The Best of October 2007
Rudolph Jaenisch recounts the differences between Iranian and American stem cell researchers. Adult stem cell expert Marcus Grompe explains his philosophical dilemma. UK officials fret about embryonic stem cell banks, and Bernadette Tansey provides a deeper analysis of a San Francisco cell banking company (see TSC’s Stem Cell Bank posts). The Pope wags his [...]
October 25, 2007
Massachusetts scrubs a blemish
A couple of weeks ago, we learned that Massachusetts, while categorized as green in TSCB’s StateWatch rankings (see 24 July’s What Color is Your State?) was trying to polish off a legal blemish that keeps it from fully embracing embryonic stem cell research.
Under state law, scientists there can’t use embryos made solely for research purposes. [...]
October 23, 2007
Louisiana: children in freezers
Louisiana earned a bright orange ranking in our StateWatch list of US stem cell legislation (for the full series of posts, navigate to StateWatch using the file cloud on the upper right).
There are a handful of states with laws on their books from the 1970’s and early 1980’s, written in fearful reaction to Roe v. [...]
October 18, 2007
Impossible Policy
Monya Baker is the editor of Nature Reports Stem Cells, and is a regular contributor to The Stem Cell.
***************
by Monya Baker
Imagine a school principal who says he wants to learn how best to incorporate new technologies into the classroom but forbids participation by the most enthusiastic and recently trained teachers. This is, essentially, what [...]
October 16, 2007
11 Useful Stem Cell Traits
by Christopher Scott
While mulling over today’s post, I went to this UK stem cell company’s website. ReNeuron develops stem cell therapies for stroke, Parkinson disease, Type 1 diabetes and diseases of the retina. They focus on adult stem cells for brain disease and diabetes. They isolate the cells from aborted human fetal tissue.
ReNeuron does [...]
October 13, 2007
What is an ESCRO?
Jennifer McCormick studies stem cell policy, law, and ethics at Stanford University and is a contributor to The Stem Cell
__________________________
by Jennifer McCormick, PhD
Embryonic Stem Cell Research Oversight (ESCRO) committees are relatively new on the research scene, having been one of the recommendations made in the 2005 National Academies’ Guidelines for Human Embryonic Stem Cell Research. [...]
October 10, 2007
Way Small Gonads
By Christopher Scott
A couple of months ago, I described the stem cell niche as: “the neighborhood within, the specific environment where stem cells can be found…the [niche] provides services to ensure survival and protection, enticing stem cells to stay put. Inside the niche, stem cells put their genes for specialization on hold.” (Use the calendar [...]
October 9, 2007
PBS and Norway
Bulletin from The Department of Reversed Order of Importance
A podcast from yesterday’s PBS broadcast of The News Hour on the state of stem cell research in California, including three of us at The Stem Cell. Link to more podcasts via the header tab.
A Nobel Prize in medicine for an embryonic stem cell pioneer, Sir Martin [...]
October 11, 2007
post riposte: Blood Cells to Save the Heart
Fresh comment from two readers who support the social benefit of early clinical stem cell research for heart disease. Scroll down to find the post and comment.
In early clinical trials, there can be a tension between the personal liberty of a seriously ill person who wishes to choose a novel treatment without enrolling in a [...]
2 Comments
Filed under adult stem cells, comment
Tags: adult stem cells, clinical trials